# Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells

> **NCT03628612** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Autolus Limited** · enrollment: 500 (estimated)

## Conditions studied

- Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy
- Multiple Myeloma
- DLBCL
- ALL, Adult and Pediatric
- T Cell Lymphoma

## Interventions

- **BIOLOGICAL:** AUTO CAR T cell therapy

## Key facts

- **NCT ID:** NCT03628612
- **Lead sponsor:** Autolus Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2018-08-02
- **Primary completion:** 2043-07
- **Final completion:** 2043-12
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2025-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03628612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03628612, "Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03628612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*